Novel cancer vaccine targets oncogenes known to evade immunity in melanoma and neuroblastoma models
Source: EurekAlert!, April 2021
A personalized tumor cell vaccine strategy targeting Myc oncogenes combined with checkpoint therapy creates an effective immune response that bypasses antigen selection and immune privilege, according to a pre-clinical study for neuroblastoma and melanoma. The neuroblastoma model showed a 75% cure with long-term survival, researchers at Children’s National Hospital found.
Myc is a family of regulator genes and proto-oncogenes that help manage cell growth and differentiation in the body.